0001642545-24-000012.txt : 20240118 0001642545-24-000012.hdr.sgml : 20240118 20240118201525 ACCESSION NUMBER: 0001642545-24-000012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240116 FILED AS OF DATE: 20240118 DATE AS OF CHANGE: 20240118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Godshall Douglas Evan CENTRAL INDEX KEY: 0001404227 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38829 FILM NUMBER: 24543448 MAIL ADDRESS: STREET 1: SUITE 4 LEVEL 46 2 PARK STREET CITY: SIDNEY STATE: C3 ZIP: 2000 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Shockwave Medical, Inc. CENTRAL INDEX KEY: 0001642545 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 270494101 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5403 BETSY ROSS DRIVE CITY: SANTA CLARA STATE: CA ZIP: 95054 BUSINESS PHONE: (510) 279-4262 MAIL ADDRESS: STREET 1: 5403 BETSY ROSS DRIVE CITY: SANTA CLARA STATE: CA ZIP: 95054 FORMER COMPANY: FORMER CONFORMED NAME: ShockWave Medical, Inc. DATE OF NAME CHANGE: 20150515 4 1 wk-form4_1705626913.xml FORM 4 X0508 4 2024-01-16 0 0001642545 Shockwave Medical, Inc. SWAV 0001404227 Godshall Douglas Evan C/O SHOCKWAVE MEDICAL, INC. 5403 BETSY ROSS DRIVE SANTA CLARA CA 95054 1 1 0 0 President & CEO 1 Common Stock 2024-01-16 4 M 0 10000 3.416 A 151057 D Common Stock 2024-01-16 4 S 0 300 215.54 D 150757 D Common Stock 2024-01-16 4 S 0 6150 216.87 D 144607 D Common Stock 2024-01-16 4 S 0 1302 217.97 D 143305 D Common Stock 2024-01-16 4 S 0 1248 219.27 D 142057 D Common Stock 2024-01-16 4 S 0 1000 220 D 141057 D Common Stock 2024-01-17 4 A 0 22078 0 A 163135 D Common Stock 2024-01-18 4 F 0 10250 217.78 D 152885 D Stock Option 3.416 2024-01-16 4 M 0 10000 0 D 2027-05-09 Common Stock 10000 304799 D All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $215.23 to $216.18. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $216.47 to $217.41. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $217.49 to $218.43. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $218.70 to $219.58. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $219.79 to $220.29. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Represents the vesting and settlement of a performance-based restricted stock unit award granted on February 1, 2022, resulting from the achievement of certain performance criteria related to the compound annual growth rate of the Issuers revenue during the measurement period January 1, 2022 through December 31, 2023. Fully vested. /s/ Wade Estey, as attorney-in-fact for Douglas Godshall 2024-01-18